Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
The Global Bioburden Testing Market has experienced consistent growth, with a compound annual growth rate (CAGR) of 12-15%. This growth is driven by tightening regulatory standards and an increasing ...
North America dominated the bioburden testing market with the largest share of 36.42% in 2025. The Asia Pacific is expected to be the fastest-growing region in the bioburden testing market during the ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results